Angiogenix Inc.
This article was originally published in Start Up
Executive Summary
Angiogenix believes the delivery of its novel growth factor, pleiotrophin, will lessen the need for repeated interventional procedures to treat restenosis at a fraction of the current cost of interventional (device or surgical) therapy, without the use of a permanent device or foreign graft.
You may also be interested in...
Understanding How To Develop BTK Inhibitors In MS Is Evolving
Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.
Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.
Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.